Literature DB >> 10805292

Increased hemostatic molecular markers in patients undergoing anticoagulant therapy.

H Wada1, H Ikuma, Y Mori, M Shimura, K Hiyoyama, T Nakasaki, K Onoda, N Yamada, T Ohta, J Nishioka, N Sakuragawa, H Shiku.   

Abstract

We evaluated several molecular markers of hemostasis in 92 patients with hypercoagulable states treated with anticoagulant therapy. In all patients, the average values of the international normalized ratio (INR) were 1.70 +/- 0.50; this increase in INR was not, however, significant in patients under thrombotest (TT) monitoring. There were no thrombotic or severe bleeding complications in these patients during a period of 27 months. Plasma levels of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), D-dimer, and soluble fibrin monomer (sFM) were slightly increased, suggesting that anticoagulant therapy was not completely effective in our Japanese patients based on the values of the TT. The INR was negatively correlated with TT, protein C, and protein S and particularly with TT between 10 and 80%. The range of TT was not correlated with the plasma level of TAT, PPIC, D-dimer, or sFM, but the range of INR was correlated with the plasma level of TAT, D-dimer, and sFM. The percentage of TAT, D-dimer, and sFM within normal range was significantly lower in patients with high INR. These findings show that INR is better than TT for the monitoring of warfarin therapy and that the therapeutic values of INR during the anticoagulant therapy should be > 1.7 in Japanese patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805292     DOI: 10.1055/s-2000-9813

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  1 in total

1.  Periprocedural coagulability in patients undergoing ablation of atrial fibrillation: lessons from a periablation anticoagulation strategy of a brief withdrawal of warfarin without heparin bridging.

Authors:  Akinori Sairaku; Yukihiko Yoshida; Haruo Hirayama; Yukiko Nakano; Yasuki Kihara
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.